Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

CG Oncology (CGON) Research & Development: 2023-2025

Historic Research & Development for CG Oncology (CGON) over the last 3 years, with Sep 2025 value amounting to $27.9 million.

  • CG Oncology's Research & Development rose 42.11% to $27.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $113.5 million, marking a year-over-year increase of 58.40%. This contributed to the annual value of $82.1 million for FY2024, which is 79.45% up from last year.
  • Latest data reveals that CG Oncology reported Research & Development of $27.9 million as of Q3 2025, which was down 11.00% from $31.3 million recorded in Q2 2025.
  • CG Oncology's Research & Development's 5-year high stood at $31.3 million during Q2 2025, with a 5-year trough of $7.8 million in Q1 2023.
  • For the 3-year period, CG Oncology's Research & Development averaged around $19.5 million, with its median value being $18.5 million (2024).
  • Data for CG Oncology's Research & Development shows a peak YoY skyrocketed of 119.46% (in 2024) over the last 5 years.
  • CG Oncology's Research & Development (Quarterly) stood at $16.3 million in 2023, then spiked by 64.01% to $26.8 million in 2024, then soared by 42.11% to $27.9 million in 2025.
  • Its last three reported values are $27.9 million in Q3 2025, $31.3 million for Q2 2025, and $27.5 million during Q1 2025.